Saiid Zarrabian insider trades: Kintara Therapeutics (KTRA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Saiid reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 7, 2021 | KTRA | ↑ Buy | 50,000 | $0.63 | $31K | Direct | Dec 8, 2021 (1d) |
| Nov 14, 2017 | DMPI | ↑ Buy | 55,000 | $0.82 | $45K | Direct | Nov 16, 2017 (2d) |
| Nov 14, 2017 | DMPI | ↑ Buy | 5,900 | $0.84 | $5K | By Child | Nov 16, 2017 (2d) |
| May 14, 2015 | LJPC | ↑ Buy | 307 | $19.50 | $6K | For Children | May 15, 2015 (1d) |
| Jul 31, 2014 | LJPC | ↑ Buy | 381 | $9.53 | $4K | For Children | Aug 5, 2014 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Saiid Zarrabian's insider trades
Saiid Zarrabian is Head of Strategic Partnerships at Kintara Therapeutics (KTRA). Since Jul 31, 2014, Saiid has reported 5 open-market purchases worth $91K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (13 filings), shares returned to the company (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KTRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.